Litigation for Patent 8,058,238

US Court Litigation for Patent: 8,058,238

Patent_nolink	Case Name	Docket	Date Filed	Date Terminated	Cause	Court	Jury Demand	Link To Docket
8,058,238	Cubist Pharmaceuticals Inc. v. Hospira Inc.	1:12-cv-00367|D. Del.	2012-03-21	2014-12-08	35:271 Patent Infringement	District Court, D. Delaware	None
8,058,238	Cubist Pharmaceuticals Inc. v. Hospira Inc.	1:12-cv-01142|D. Del.	2012-09-17	2015-06-22	35:271 Patent Infringement	District Court, D. Delaware	None
8,058,238	Cubist Pharmaceuticals LLC. v. Mylan Laboratories Limited	1:13-cv-01679|D. Del.	2013-10-09	2016-02-02	35:271 Patent Infringement	District Court, D. Delaware	None
8,058,238	Cubist Pharmaceuticals Inc. v. Fresenius Kabi USA LLC	1:14-cv-00914|D. Del.	2014-07-11	2016-02-02	35:271 Patent Infringement	District Court, D. Delaware	None
8,058,238		1:15-cv-01164|D. Del.	2015-12-17	2016-03-02	35:271 Patent Infringement	District Court, D. Delaware	None
8,058,238		1:15-cv-01164|D. Del.	2015-12-16	2016-03-01	35:271 Patent Infringement	District Court, D. Delaware	None

Patent Trial and Appeal Board Cases for Patent 8,058,238

Patent	Petitioner	Status	Filing Date	Accorded Filing Date	Patent Owner	Trial Type	Trial Number	Decision Date	Inventor	Document Download
8,058,238	Agila Specialities Inc. et al.		2014-10-23	10-23-2014	Cubist Pharmaceuticals, Inc.	Inter partes review		04-28-2015	Thomas Kelleher
8,058,238	Agila Specialities Inc. et al.		2014-10-23	10-23-2014	Cubist Pharmaceuticals, Inc.	Inter partes review		04-28-2015	Thomas Kelleher
8,058,238	Agila Specialities Inc. et al.		2014-10-23	10-23-2014	Cubist Pharmaceuticals, Inc.	Inter partes review		04-28-2015	Thomas Kelleher
8,058,238	Agila Specialties Inc. et al.		2014-10-24	10-23-2014	Cubist Pharmaceuticals, Inc.	Inter partes review		04-28-2015	Thomas Kelleher
8,058,238	Fresenius Kabi USA LLC		2015-07-10	07-10-2015	Cubist Pharmaceuticals LLC	Inter partes review		01-28-2016	Thomas Kelleher
8,058,238	Fresenius Kabi USA LLC		2015-07-10	07-10-2015	Cubist Pharmaceuticals LLC	Inter partes review		01-28-2016	Thomas Kelleher